Skip to main content
Clinical Trials/IRCT201202251556N35
IRCT201202251556N35
Completed
Phase 2

The effect of intranasal oxytocin on negative symptoms in patients with chronic schizophrenia: a double blind and placebo controlled trial

Tehran University of Medical Sciences0 sites40 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
schizophrenia.
Sponsor
Tehran University of Medical Sciences
Enrollment
40
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Age between 18\-50, Diagnosis of Schizophrenia based on DSM IV 3 chronic Schizophrenia( duration of the disorder\>2 years), Minimum Score of 60 on Positive and Negative Scale

Exclusion Criteria

  • 1\- Substance dependence,2\- IQ \<70, 3\-any other mental disorder on axis I, 4\-Any serious medical or neurological problem ,5\- receiving ECT during the last 14 days, 6\- hepatic disease

Outcomes

Primary Outcomes

Not specified

Similar Trials